Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity

Dasatinib is a compound developed for chronic myeloid leukemia as a multi-targeted kinase inhibitor against wild-type BCR-ABL and SRC family kinases. Valproic acid (VPA) is an anti-epileptic drug that also acts as a class I histone deacetylase inhibitor. The aim of this research was to determine the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2014-06, Vol.9 (2), p.e98859
Hauptverfasser:	Heo, Sook-Kyoung, Noh, Eui-Kyu, Yoon, Dong-Joon, Jo, Jae-Cheol, Park, Jae-Hoo, Kim, Hawk
Format:	Artikel
Sprache:	eng
Schlagworte:	Abl protein Acids Acute myelocytic leukemia Acute myeloid leukemia Adenosine diphosphate Aged Anticonvulsants - pharmacology Apoptosis BCR protein BCR-ABL protein Biochemistry Biomedical research Bone marrow Cancer Caspase Caspase-3 Cell cycle Cell death Cell Death - drug effects Cell differentiation Cell Differentiation - drug effects Cell Line, Tumor Chemotherapy Chronic myeloid leukemia Cyclin-dependent kinases Dasatinib Differentiation Drug Synergism Enzyme inhibitors Epilepsy Extracellular signal-regulated kinase Female Fusion protein G1 phase G1 Phase Cell Cycle Checkpoints - drug effects Hematology Histone deacetylase Humans Inhibitors Kinases Leukemia Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - pathology MAP kinase Medical research Medicine Medicine and Health Sciences Middle Aged Mortality Myeloid leukemia Oncology Penicillin Prostate Protein-Tyrosine Kinases - pharmacology Pyrimidines - pharmacology Regulators Ribose Thiazoles - pharmacology Valproic acid Valproic Acid - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!